Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
October 19 2021 - 07:00AM
Oxford
Biomedica
Announces that
Boehringer Ingelheim has
Exercised
Option Relating
to a Novel Gene Therapy Treatment
for Cystic Fibrosis
Oxford, UK –
19 October
2021: Oxford Biomedica plc (LSE:OXB) (“Oxford
Biomedica” or “the Group”), a leading gene and cell therapy group,
today announces that Boehringer Ingelheim has exercised its option
to license Oxford Biomedica’s lentiviral vector technology to
manufacture, register and commercialise BI 3720931, a lentiviral
vector-based gene therapy for the treatment of cystic fibrosis
(CF).
Under the terms of the option and license
agreement with Boehringer Ingelheim, originally announced in August
2018, Boehringer Ingelheim will pay Oxford Biomedica an option
exercise fee of £3.5 million. Oxford Biomedica is further entitled
to development, regulatory and sales milestones of up to a further
£27.5 million, in addition to a tiered low single digit royalty on
net sales of a CF gene therapy product. This option exercise by
Boehringer Ingelheim follows on another recent signature of a
Development & Supply Agreement which was announced in April
2021, relating to the clinical manufacture of various types of
viral vector based products.
In parallel, Boehringer Ingelheim has also
exercised its option to license intellectual property and know-how
from IP Group and the UK Cystic Fibrosis Gene Therapy Consortium
relating to the same lentiviral vector-based product candidate for
the treatment of CF.
This innovative development partnership between
academia, Pharma and Biotech focuses on the development of a novel,
replication deficient lentiviral vector, in an inhaled formulation,
to selectively introduce a CFTR gene into the relevant target cell.
This approach has demonstrated high gene transfer efficiency and
offers the possibility of repeated administration to maintain a
therapeutic effect. In addition, the approach has the potential to
address all of the more than 2,000 different known gene mutations
across CF patients, and therefore offers a gene-independent
disease-modifying treatment option for patients.
Should the program progress into clinical
development, Oxford Biomedica expects to produce large quantities
of lentiviral vectors using its highly efficient GMP-compliant
manufacturing process in bioreactors.
To read the full Boehringer Ingelheim press
release please follow this link:
http://www.boehringer-ingelheim.com/press-release/cystic-fibrosis-genetherapy-development-option-excercise
John Dawson, Chief Executive Officer of
Oxford
Biomedica,
said: “We have enjoyed working with Boehringer
Ingelheim, IP Group, and the UK Cystic Fibrosis Gene Therapy
Consortium since 2018. Building on the great progress made to date,
we are delighted that Boehringer Ingelheim, one of the world’s
leading respiratory medicine organisations, has chosen to exercise
the option to license Oxford Biomedica’s lentiviral vector
manufacturing technology for this highly innovative inhaled cystic
fibrosis gene therapy formulation developed by the UK Cystic
Fibrosis Gene Therapy Consortium. This partnership is central to
our company’s mission of delivering life changing gene therapies to
patients and has the potential to provide a new therapeutic option
for many cystic fibrosis patients globally.”
Clive R. Wood, Ph.D., Corporate Senior
Vice President and Global Head of Discovery Research at Boehringer
Ingelheim, said: “Since 2018, Boehringer Ingelheim has
sponsored research and development activities with the UK Cystic
Fibrosis Gene Therapy Consortium and Oxford Biomedica. The shared
success achieved with our partners in this potentially
revolutionary project makes us confident that we can now further
accelerate this highly innovative therapeutic approach. With our
leadership in the discovery and development of therapies in
respiratory diseases combined with the gene therapy and
manufacturing knowledge of our partners, we aim to bring the next
breakthrough to patients suffering from CF, who are desperately
waiting for better options.”
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E:
ir@oxb.com
John Dawson, Chief Executive OfficerStuart Paynter, Chief
Financial OfficerSophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709
5700
Mary-Jane Elliott / Matthew Neal
About Oxford BiomedicaOxford
Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for
serious diseases. Oxford Biomedica and its subsidiaries (the
"Group") have built a sector leading lentiviral vector delivery
platform (LentiVector®), which the Group leverages to develop in
vivo and ex vivo products both in-house and with partners. The
Group has created a valuable proprietary portfolio of gene and cell
therapy product candidates in the areas of oncology, CNS disorders
and liver diseases. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb, Sio
Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and
Boehringer Ingelheim, through which it has long-term economic
interests in other potential gene and cell therapy products.
Additionally, the Group has signed a 3-year master supply and
development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 740 people. Further
information is available at www.oxb.com
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough
therapies that improve the lives of humans and animals. As a
leading research-driven biopharmaceutical company, the company
creates value through innovation in areas of high unmet medical
need. Founded in 1885 and family-owned ever since, Boehringer
Ingelheim takes a long-term perspective. Around 52,000 employees
serve more than 130 markets in the three business areas, Human
Pharma, Animal Health, and Biopharmaceutical Contract
Manufacturing. Learn more at www.boehringer-ingelheim.com
About Cystic FibrosisCystic
Fibrosis is a rare, progressive, life-threatening disease that
results in severe dysfunction and persistent infections of the lung
affecting 70,000 people worldwide. It is caused by a defective or
absent protein that results from mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. This
innovative development partnership among academia, life science
investors, pharma, and biotech focusses on the advancement of BI
3720931, a novel, replication deficient lentiviral vector, in an
inhaled formulation, which selectively introduces a healthy CFTR
gene into the relevant target cells.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2023 to Mar 2024